Samsara Vision update: Concerto trial recruiting patients with late-stage AMDOctober 6th 2022
Tom Ruggia, President and CEO of Samsara Vision, provides updates on the lead asset for late-state age-related macular degeneration: Smaller-incision, new generation, implantable miniature telescope (SING IMT).
Risk of rhegmatogenous retinal detachment rises following cataract surgeryOctober 4th 2022
The investigators undertook a study to determine the incidence of rhegmatogenous retinal detachments 1 year after cataract using the IRIS Registry data and to determine the demographic features, ocular comorbidities, and intraoperative factors associated with an increased risk of detachment development.
Faricimab for nAMD: Safe, effective, lower treatment burden compared with aflibercept in pooled TENAYA, LUCERNE Phase 3 trialsOctober 2nd 2022
The AVONELLE-X long-term extension study will continue to evaluate the efficacy, durability, and safety of faricimab in patients with neovascular AMD.
Late-breaking: Janssen announces data from 2 gene therapy programsOctober 2nd 2022
Janssen noted that results from Phase 1/2 MGT009 study demonstrate safety profile of investigational gene therapy botaretigene sparoparvovec (AAV-RPGR) and suggest sustained vision improvement in patients with X-linked retinitis pigmentosa.
Acute retinal necrosis: Retinal detachment rates are unaffected by early treatment with intravitreal antivirals, vitrectomyOctober 2nd 2022
The results also showed that, compared to use of systemic antivirals alone, treatment with adjunctive intravitreal injections or early pars plana vitrectomy did not affect the time to development of retinal detachments.
Faricimab eradicates center-involved DME faster than afliberceptOctober 2nd 2022
The data analysis indicated that patients achieved robust visual gains and central subfield thickness reductions with faricimab dosed every 8 weeks and with PTI dosing up to every 16 weeks. The gains were sustained through year 2 of the trials.
Continuous range-of-motion IOL scores high in patient satisfactionSeptember 30th 2022
Investigators reported that the safety and efficacy of the Tecnis Synergy IOL model ZFR00V indicates that it may be a good option for patients who desire meaningful gains in uncorrected visual acuity at all distances.
Pediatric patients have higher incidence of new strabismus following tube shunt surgery than adult patientsSeptember 30th 2022
13% of pediatric patients had new-onset strabismus after a tube shunt procedure; in contrast, 0% of adults had new-onset strabismus after tube shunt surgery (at 6 months or at last follow-up).
YOSEMITE, RHINE treat-and-extend data show favorable results for faricimab for the treatment of DMESeptember 30th 2022
Roger A. Goldberg, MD, MBA, discusses his 2022 AAO poster: "T&E-Based Personalized Treatment Interval Dynamics in the YOSEMITE/RHINE Trials of Faricimab in DME."
Using the IRIS registry to analyze ancillary testing patterns on a per patient basisJanuary 6th 2022
Ted Leng, MD, discusses his presentation, “Variations in Vitreoretinal Physician Utilization of Ancillary Testing: An IRIS Registry Analysis” during Retina Specialty Day at AAO 2021.
Brolucizumab shows evidence of retinal drying in wet AMDDecember 15th 2021
Jill Hopkins, MD, discusses results from phase 3a of the Merlin trial for brolucizumab as a treatment for wet AMD and provides updates on KESTREL and KITE trials for the treatment of diabetic macular edema.
ARMOR study: data sheds light on antibiotic resistance in ophthalmologyDecember 8th 2021
At the 2021 American Academy of Ophthalmology annual meeting, Penny Asbell, MD, FACS, MBA, discussed data from the ARMOR study and its effects on treating ophthalmic infections, such as endophthalmitis.